Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1177648 · FYE Sep 30 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $12.61Day −0.94%Mkt cap $367M1Y +57.0%Off 52W high −26.5%Vol (1Y) 109.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,356 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest8.4% of sh out |
| Days to cover12.8d |
| 13F net flow (QoQ)+4.31% |
| Top-10 13F concentration72.5% |
| Next report (est.)2026-08-10 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$69.2M |
| Earnings (TTM)-$62.0M |
| ROE−84.6% |
| Net margin−125.4% |
| ROIC−108.8% |
| Sales growth 3Y−8.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−20.0% |
| 1Y+57.0% |
| 3Y−31.6% |
| 5Y−70.3% |
| 10Y−40.0% |
| Since incept. (ann.)−2.3% |
Total return through 2026-07-28 · series begins 2013-03-21. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)109.5% |
| Ann. volatility (3Y)83.4% |
| Sharpe (1Y)0.82 |
| Sharpe (3Y)0.21 |
| Max drawdown (1Y)−34.3% |
| Max drawdown (3Y)−78.5% |
| Beta (3Y vs SPY)1.53 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 3.8M | $48M | 13.01% | +1.5% |
| BlackRock, Inc. | 3.1M | $39M | 10.67% | +0.9% |
| FARALLON CAPITAL MANAGEMENT LLC | 2.9M | $36M | 9.88% | +3.6% |
| Krensavage Asset Management, LLC | 2.9M | $36M | 9.86% | +3.6% |
| Deep Track Capital, LP | 2.0M | $25M | 6.73% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $15M | 4.05% | new |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 948,904 | $12M | 3.26% | new |
| Spruce Street Capital LP | 932,598 | $12M | 3.21% | +139.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.45 | — | $17.2M | +15.0% |
| 2025-12-31 | 2026-02-09 | −$0.42 | — | $18.6M | +9.8% |
| 2025-09-30 | 2025-11-17 | — | — | $15.1M | +3.5% |
| 2025-06-30 | 2025-08-11 | −$0.85 | — | $18.3M | +1.9% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-10 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Royalty 100%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
